MacFarlane M D
Fed Proc. 1975 Jan;34(1):108-10.
A specially stabilized form of procaine hydrochloride (Gerovital H3) has been shown to be a more potent inhibitor of monoamine oxidase than procaine HCl itself and a weaker inhibitor of this enzyme than iproniazid. This preparation was studied to determine its mode of interaction with monoamine oxidase using purified rat brain mitochondrial monoamine oxidase as the enzyme source. Reaction velocities were determined spectrophotometrically by quantitating the rate of appearance of 4-hydroxyquinoline from kynuramine. Dilutional studies comparing the mechanism of inhibition of monoamine oxidase produced by Gerovital H3 and by ipronizid demonstrated that Gerovital H3 was a reversible inhibitor of monoamine oxidase. Analysis of studies using Lineweaver-Burk and Dixon plots revealed that Gerovital H3 was a fully competitive inhibitor of monoamine oxidase. That Gerovital H3 is a weak, reversible, competitive inhibitor of monoamine oxidase may explain the absence of adverse reactions associated with the clinical use of Gerovital H3 as compared to the severe adverse reactions that have been associated with the use of irreversible monoamine oxidase inhibitors.
一种特殊稳定形式的盐酸普鲁卡因(杰诺维特H3)已被证明是一种比盐酸普鲁卡因本身更强效的单胺氧化酶抑制剂,且比异烟肼对该酶的抑制作用更弱。使用纯化的大鼠脑线粒体单胺氧化酶作为酶源,对该制剂进行了研究,以确定其与单胺氧化酶的相互作用模式。通过分光光度法定量犬尿胺生成4-羟基喹啉的速率来测定反应速度。比较杰诺维特H3和异烟肼对单胺氧化酶抑制机制的稀释研究表明,杰诺维特H3是单胺氧化酶的可逆抑制剂。使用林-贝氏(Lineweaver-Burk)和狄克逊(Dixon)图的研究分析表明,杰诺维特H3是单胺氧化酶的完全竞争性抑制剂。杰诺维特H3是一种弱的、可逆的、竞争性单胺氧化酶抑制剂,这可能解释了与使用不可逆单胺氧化酶抑制剂相关的严重不良反应相比,杰诺维特H3临床使用时没有不良反应的原因。